[HIV protease inhibitors].
Fujisawa
Y
Y
Pharmaceutical Research Division, Takeda Chemical Industries, Ltd., Osaka, Japan.
Kakinuma
A
A
D000164:Acremonium / Q000378:metabolism; D000595:Amino Acid Sequence; D001483:Base Sequence; D018797:Cell Cycle Proteins; D002569:Cerulenin / Q000302:isolation & purification / Q000494:pharmacology; D015971:Gene Expression Regulation, Enzymologic; D005815:Genetic Code; D016333:HIV Protease / Q000737:chemistry / Q000235:genetics; D017320:HIV Protease Inhibitors; D008969:Molecular Sequence Data; D009842:Oligopeptides / Q000494:pharmacology; D010436:Pepstatins / Q000494:pharmacology; D020648:Peptide Elongation Factor 1; D011487:Protein Conformation; D011506:Proteins / Q000494:pharmacology; D013402:Sugar Alcohols / Q000494:pharmacology; D014633:Valine / Q000031:analogs & derivatives / Q000494:pharmacology
D018797:Cell Cycle Proteins; C503234:EEF1A2 protein, human; D017320:HIV Protease Inhibitors; D009842:Oligopeptides; D010436:Pepstatins; D020648:Peptide Elongation Factor 1; D011506:Proteins; D013402:Sugar Alcohols; C014195:Streptomyces pepsin inhibitor; C065300:A 74704; C066511:JG 365; C073513:KNI 102; D002569:Cerulenin; D016333:HIV Protease; D014633:Valine; C031375:pepstatin